INTRODUCTION AND OBJECTIVES:
Suicide is a significant problem in the general and chronic pain population. Although two studies have examined the prevalence and predictors of suicidal ideation in people suffering from Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS), these studies are limited by their sample selection, assessment of suicidal thinking and behaviour or risk, and the lack of any direct assessment of variables in current theories of suicide. The current study examines the prevalence of suicide risk and the significance of various demographic and biopsychosocial factors that are theoretically implicated in the prediction of suicide risk in an IC/BPS sample.
METHODS: Female patients currently suffering from IC/BPS (N¼813) were recruited from online support groups and complete an online questionnaire containing measures of demographic, pain, symptoms, and psychosocial variables.
RESULTS: The sample was split into groups of suicide risk, based on an adult general population cut-off score of ¼7 for the SBQ-R, creating a not at risk group (n ¼ 503, M ¼ 3.96, SD ¼ 1.11) and an at risk group (n ¼ 310, M ¼ 9.73, SD ¼ 2.65). This data split showed that 310 participants, or 38.1% of the sample, were at risk for suicide. Alternatively, using the more conservative cut-off score of ¼8 (based on an adult inpatient population), 233 participants, or 28.7%, were at risk for suicide (see Figure 1) . In regression analyses testing empirically/theoretically implicated contributors to suicidal behaviour, exposure to suicide, pain catastrophizing, psychache, hopelessness and perceived burdensomeness were found to significantly predict suicide risk. Further, regressions for low, moderate and severe pain patients groups showed that hopelessness was the strongest predictor of suicide risk in low pain patient group; psychache in the moderate pain group: and perceived burdensomeness in severe pain group.
CONCLUSIONS: The high prevalence of suicidality presented in this study denotes the imperative of recognizing suicidality within the IC/BPS population. Further, the identified psychosocial risk factors will be useful in improving screening and to anchor potential treatment targets for suicidality in IC/BPS.
Source of Funding: NONE

MP29-16 IMPROVING THE UTILITY OF CLINICAL PHENOTYPING IN INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME: FROM UPOINT TO INPUT
Alice Crane*, Jessica Lloyd, Daniel Shoskes, Cleveland, OH INTRODUCTION AND OBJECTIVES: The phenotyping system UPOINT has proven effective in classifying patients with Urologic Pelvic Pain Syndromes in a clinically meaningful way and to guide therapy. While highly successful in men with chronic pelvic pain syndrome (CPPS), UPOINT is more limited in patients with Interstitial Cystitis/ Painful Bladder Syndrome (IC/PBS) since by definition all patients have the Urinary and Organ specific phenotype. Furthermore, AUA guidelines recommend a sequential tiered approach to therapy rather than the multimodal UPOINT scheme. We sought to modify UPOINT to be more practical and efficacious for IC/PBS METHODS: We developed a new phenotype by removing the Urinary and Organ specific domains from UPOINT and adding a Hunner's Ulcers (U) domain, since these patients benefit from phenotype specific therapies (fulguration, cyclosporine). This yields "INPUT": Infection, Neurologic/Systemic, Psychosocial, Ulcers and Tenderness of Muscles. We applied this system retrospectively to our previously validated upointmd.com IC/PBS database. Symptoms were measured by the Genitourinary Pain Index (GUPI) (valid for men and women). The database was searched for patients with complete data to assess the INPUT domains and include GUPI. Men were included if they reported pain relieved by voiding and/or presence of Hunner's ulcers. Groups were compared with ANOVA, Mann-Whitney, t test or Chi squared when appropriate and correlated with Spearman r.
RESULTS: There were 239 patients, 154 female (64%) with age range 18-79 (mean 41.8). Incidence of domains was Infection 11%, Neurologic/Systemic 51%, Psychosocial 81%, Ulcers 18% and Tenderness 85%. Mean total domains was 2.46 (range 0-5) and 65% had 2 or 3 positive domains while only 5% had none. There was a stepwise increase in GUPI score with increasing number of positive INPUT domains (ANOVA for differences between groups p<0.0001, Correlation by Spearman r¼0.355 p<0.0001). Presence of Hunner's ulcers increased mean symptom score (25.7 vs 29.7, p¼0.004) and indeed each of the domains significantly increased total GUPI score except for Infection.
CONCLUSIONS: The INPUT phenotype in IC/PBS appears to replicate the validity and potential clinical utility of UPOINT in CPPS.
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THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 Patients have a diversity of phenotypes and more positive domains correlate with more severe symptoms. Since 95% of patients have at least 1 positive domain it may benefit patients to receive multimodal therapy up front for these extra domains (eg. pelvic floor physical therapy, fulguration of ulcers) rather than relying on a sequential tiered approach.
Source of Funding: None
MP29-17 MAST CELL SUBTYPES: IMPLICATIONS FOR THE PATHOGENESIS OF INTERSTITIAL CYSTITIS
Brian Birch*, Shabana Malik, Bashir Lwaleed, Southampton, United Kingdom INTRODUCTION AND OBJECTIVES: Painful bladder syndrome/interstitial cystitis (PBS/IC) is a chronic inflammatory disorder of the urinary bladder. Although its pathogenesis is largely unknown, there is evidence that it is related to mast cell (MC) proliferation and activation in a subset of patients. The objective of this study was to compare the difference in MC subtype, density, and distribution, between normal and PBS/IC bladder tissue.
METHODS: Full-thickness bladder tissue was collected from patients with PBS/IC (n¼14), and from patients with normal histological findings (n¼4). Samples were paraffin-embedded, and sectioned for immunohistochemistry. Mast cell subtypes were identified using a mast cell tryptase antibody (AA1), and anti-mast cell chymase antibody (CC1). Slides were photographed at a standard magnification, and positively stained mast cells were quantified using ImageJ software.
RESULTS: The distribution of AA1 positive mast cells within the layers of the bladder wall of PBS/IC and control individuals is shown in figure 1 . The distribution of mast cell subtypes within the layers of the bladder wall of PBS/IC individuals is shown in figure 2 . These results showed a significant difference in the density of MCs between each layer of the bladder wall in PBS/IC tissue (p<0.05). It was also shown that PBS/IC tissue contains a higher number of MCs compared to controls, with the largest difference in density between the two groups found in the lamina propria layer. There is also a significant difference in the density of MC subtype (p<0.05).
CONCLUSIONS: These findings suggest that MC numbers are significantly increased in PBS/IC bladder tissue, with a significant difference in subtype and density within the layers of the bladder. This may provide new insight into the role of MCs in PBS/IC, further our understanding of the pathogenesis of the disease, and develop treatment strategies. The injection procedure is not standardized yet. The aim of the present study is to evaluate the efficacy of Botulinum Toxin A (BoNT A) intravesical injections in patients with BPS after a standarized injection procedure. Secondarily, we evaluate the complications, duration of response, and the effect of adding hydrodistension (HD) during the procedure.
METHODS: Fourty one patients with BPS treated between January 2008 to march 2015 were retrospectively evaluated. All patients received 200 UI of BoNT A injected under cystoscopic control: 100 UI in the trigone plus 100 UI in the detrusor. In 26 patients HD was also performed. Three days voiding chart, Visual Analogue Scale (VAS) for pain, Global Response Assessment (GRA) and urodynamic parameters were evaluated at baseline and after treatment.
RESULTS: After a mean follow-up of 36 months, 25 patients (61%) reported subjective improvement (-3 points in VAS) lasting during 7 months as an average (range 3-18). Eight patients (20%) reported total relief of pain (VAS ¼ 0). Daytime and nighttime urinary frequencies were reduced, reaching statistically significance only at night (from 7 to 4 times p < 0.001). Functional bladder capacity measured by voiding chart increased significantly (from 73 to 115 ml p < 0.003). Mean voided volume at uroflowmetry increased significantly (from 100 to 191 ml p < 0.001). Four patients reported incomplete bladder emptying, however there were no significant increase in postvoid residual volume. The comparison between HD and nonHD groups of patients did not show a significant difference in objective parameters. However, the HD group showed a significantly better GRA (7 versus 4 p <0.02).
CONCLUSIONS: The proposed procedure of BoNT A injection (100UI trigone + 100 UI detrusor plus HDT) was effective and safe in
